Immunotherapy combinations based on nivolumab entail lower costs for grade 3/4 adverse events than those using pembrolizumab, a finding that could inform treatment decisions.

Immune checkpoint inhibitors have changed the future of cancer care. These powerful treatments use the body’s own immune ...

Two such drugs are nivolumab and pembrolizumab. Both are FDA approved for the treatment of non-small cell carcinomas (among others) and block PD-1 (programmed cell death) mediated silencing of the ...

Reducing the infusion time for nivolumab and pembrolizumab to 10 minutes is feasible and safe, according to researchers.

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...

Dr. Davide Soldato So, in terms of clinical applicability, do you see this combination of pembrolizumab and bevacizumab - and of course, as we mentioned, this was a phase 2 trial. The number of ...

Neoadjuvant and adjuvant pembrolizumab added to standard care significantly improves event-free survival in HNSCC.

The FDA narrowed the indications for pembrolizumab (Keytruda) and nivolumab (Opdivo) in gastric, gastroesophageal junction (GEJ), and esophageal cancers, according to letters sent to the ...